Agomelatine: AGO 178, AGO178, S 20098

Drugs in R and D

Volumn 9, Issue 3, 2008, Pages 177-183

[No Author Info available]

Author keywords

Agomelatine, therapeutic use; Antidepressants, therapeutic use; Depression; Research and development

Indexed keywords

5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; ACEBUTOLOL; AGO 178; AGOMELATINE; ALCOHOL; CLORAZEPATE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PAROXETINE; PLACEBO; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR;

ABDOMINAL PAIN; ANXIETY DISORDER; BEDTIME DOSAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; FINLAND; FOLLOW UP; FRANCE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MOOD DISORDER; MOUSE; NONHUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; RELAPSE; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOUTH AFRICA; TREATMENT REFUSAL; UNITED STATES; WEIGHT GAIN;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS;

EID: 43249118878     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200809030-00005     Document Type: Review

References (29)

1. Novartis, Servier. Novartis and Servier sign licensing agreement for a novel treatment of Major Depressive Disorder. Media Release: 29 Mar 2006. Available from URL: http://www.novartis.com
2. SPRI Clinical Trials. SPRI Clinical Trials Now Enrolling Patients for Study of New Treatment for Depression. Media Release: 15 Oct 2007. Available from URL: http://www.spristudy.com
3. Novartis International AG. Novartis highlights strong R&D pipeline, plans for multiple new product launches and novel projects moving into late-stage trials. Media Release: 28 Nov 2006. Available from URL: http://www.novartis.com
4. Servier. Valdoxan(R), the First Melatonergic Antidepressant, Confirms its Efficacy in Preventing Relapse Whatever the Severity of the Depression. Media Release: 15 Oct 2007. Available from URL: http://www.newswire.ca
5. Goodwin GM, Rouillon F, Emsley R. Long-term efficacy of agomelatine, a novel antidepressant, in the prevention of relapse in out-patients with major depressive disorder. European Neuropsychopharmacology 17 (Suppl. 4): 361-362, Oct 2007
6. Fabiano A, de Leeersnyder H. Agomelatine efficacy on major sleep disturbances in Smith-Magenis syndrome: an exploratory, open study in children. European Neuropsychopharmacology 17 (Suppl. 4): 567, Oct 2007
7. Stein DJ, Ahokas A, Fabiano A. Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled, study. European Neuropsychopharmacology 17 (Suppl. 4): 509-510, Oct 2007
8. Gunay I, Fava M. Agomelatine, a novel antidepressant, has a favorable safety and tolerability profile in the treatment of major depressive disorder. 160th Annual Meeting of the American Psychiatric Association: 162, 19 May 2007
9. Hard ML, Tang M, Kaplan HL, et al. Interaction of repeated oral agomelatine, a novel antidepressant, and ethanol in healthy volunteers. International Journal of Neuropsychopharmacology 7 (Suppl. 1): 181-182 (plus poster) abstr. P01.184, 22 Jun 2004
10. Calabrese F, Pescara F, Racagni G, et al. Modulation of Arc and BDNF following acute and chronic administration of agomelatine in rats. European Neuropsychopharmacology 17 (Suppl. 4): 333-334, Oct 2007
11. Corbach S, Schmelting B, Fuchs E, et al. Comparison of agomelatine and melatonin for effects in chronically stressed tree shrews, an animal model of depression. European Neuropsychopharmacology 17 (Suppl. 4): 364-365, Oct 2007
12. Barbiero VS, Zappettini S, Mocaer E, et al. The novel antidepressant agomelatine reduces release of glutamate and related presynaptic mechanisms in rat hippocampus. European Neuropsychopharmacology 17 (Suppl. 4): 365, Oct 2007
13. Bertaina-Anglade V, Seguin L, Mocaer E, et al. Evaluation of cognition enhancing properties of agomelatine in the object recognition task in rats. European Neuropsychopharmacology 17 (Suppl. 4): 366-367, Oct 2007
14. Bourin M, Mocäer E, Porsolt R. Efficacy and behavioural profile of S 20098 in the despair test after acute and repeated administration. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 65, Jun 2002
15. Barden N, Labb́e M, Vacher R, et al. Antidepressant action of S-20098 (agomelatine) in a transgenic mouse model. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 64, Jun 2002
16. Bertaina-Anglade V, Mocaër E, Drieu la Rochelle C. Antidepressant-like action on S 20098 (agomelatine) in the learned helplessness test. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 65, Jun 2002
17. Papp M, Gruca P, Mocäer E. Antidepressant activity of S 20098 (agomelatine) in the chronic mild stress model of depression in the rat. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 65, Jun 2002
18. Papp M, Gruca P, Boyer P-A, et al. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28: 694-703, Apr 2003
19. Millan MJ, Dekeyne A, Gobert A, et al. Anxiolytic properties of agomelatine (S20098), a dual melatoninergic and serotonergic antidepressant, in rodents. International Journal of Neuropsychopharmacology 7 (Suppl. 1): 201 (plus poster) abstr. P01.263, 22 Jun 2004
20. Mocaer E, Tobler I, Danhof M. S-20098, a potent melatonin agonist is devoid of sleep-inducing effects at chronobiotic doses. Journal of Sleep Research 3 (Suppl. 1): 168, Jun 1994
21. Redman J, Francis A, Smith A. Possible sites of action of the melatonin agonist S20098. Neuropsychopharmacology 10 (Suppl. Part 2): 173, May 1994
22. Jaffard R, Toumane A, Mocaer E. Facilitatory effects of S-20098 on learning and memory in mice depend on circadian rhythms. European Neuropsychopharmacology 3 (Spec. issue): 449, Sep 1993
23. Wiley JL, Dance ME, Balster RL. Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. Psychopharmacology 140: 503-509, No. 4, Dec 1998
24. Lôo H, D;haenen H, Hale A. A double-blind trial of S-20098 in patients with major depressive or bipolar II disorders: dose-ranging study. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 146, Jun 2002
25. Lôo H, D'haenen H, Hale A. A double-blind study of S-20098 in patients with major depressive or bipolar II disorders: effect on remission. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 145, Jun 2002
26. Lôo H, D'haenen H, Hale A. S-20098 in patients with major depressive or bipolar II disorders: efficacy in severely depressed patients. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 145, Jun 2002
27. Lôo H, D'haenen H, Hale A. A double-blind study of S-20098 in patients with major depressive or bipolar II disorders: effects on anxiety. International Journal of Neuropsychopharmacology 5 (Suppl. 1): 145, Jun 2002
28. Quera-Salva M-A, Vanier B, Chapotot F, et al. Effect of agomelatine on the sleep EEG in patients with major depressive disorder. European Neuropsychopharmacology 15 (Suppl. 3): 435-436 (plus poster) abstr. P.2.102, Oct 2005
29. Schatzberg AF, Zaninelli R. Agomelatine, a novel antidepressant, is effective in major depressive disordr across gender and severity od depression. 160th Annual Meeting of the American Psychiatric Association: 163, 19 May 2007